Vertex Short Term Debt from 2010 to 2024

VRTX Stock  USD 461.71  10.74  2.38%   
Vertex Pharmaceuticals Short Term Debt yearly trend continues to be fairly stable with very little volatility. Short Term Debt is likely to outpace its year average in 2024. During the period from 2010 to 2024, Vertex Pharmaceuticals Short Term Debt regression line of annual values had significance of  0.72 and arithmetic mean of  52,938,333. View All Fundamentals
 
Short Term Debt  
First Reported
1990-12-31
Previous Quarter
83.7 M
Current Value
-220 M
Quarterly Volatility
70.4 M
 
Oil Shock
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Vertex Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vertex Pharmaceuticals' main balance sheet or income statement drivers, such as Total Revenue of 10.4 B, Gross Profit of 9 B or Other Operating Expenses of 6.3 B, as well as many indicators such as Price To Sales Ratio of 10.09, Dividend Yield of 0.0 or PTB Ratio of 7.46. Vertex financial statements analysis is a perfect complement when working with Vertex Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Vertex Pharmaceuticals Correlation against competitors.
For more information on how to buy Vertex Stock please use our How to Invest in Vertex Pharmaceuticals guide.

Latest Vertex Pharmaceuticals' Short Term Debt Growth Pattern

Below is the plot of the Short Term Debt of Vertex Pharmaceuticals over the last few years. It is Vertex Pharmaceuticals' Short Term Debt historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Vertex Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Short Term Debt10 Years Trend
Very volatile
   Short Term Debt   
       Timeline  

Vertex Short Term Debt Regression Statistics

Arithmetic Mean52,938,333
Coefficient Of Variation233.29
Mean Deviation76,325,822
Median32,012,000
Standard Deviation123,501,082
Sample Variance15252.5T
Range594.4M
R-Value(0.1)
Mean Square Error16261.7T
R-Squared0.01
Significance0.72
Slope(2,760,196)
Total Sum of Squares213535.2T

Vertex Short Term Debt History

202487.9 M
202383.7 M
202289.4 M
202180.2 M
2020-275 M
201930.3 M
20189.8 M

About Vertex Pharmaceuticals Financial Statements

Vertex Pharmaceuticals investors use historical fundamental indicators, such as Vertex Pharmaceuticals' Short Term Debt, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Vertex Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Short Term Debt83.7 M87.9 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Vertex Stock Analysis

When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.